Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis C patients

: a nation-wide real-world Taiwanese cohort (T-COACH)

Pei-Chien Tsai\(^{1,2,*}\), Chi-Yi Chen\(^3,*\), Hsing-Tao Kuo\(^4\), Chao-Hung Hung\(^5\), Kuo-Chih Tseng\(^6\), Hsueh-Chou Lai\(^7\), Cheng-Yuan Peng\(^7\), Jing-Houng Wang\(^8\), Jyh-Jou Chen\(^9\), Pei-Lun Lee\(^9\), Rong-Nan Chien\(^10\), Chi-Chieh Yang\(^11\), Gin-Ho Lo\(^12\), Jia-Horng Kao\(^13,14\), Chun-Jen Liu\(^13,14\), Chen-Hua Liu\(^13,14\), Sheng-Lei Yan\(^15\), Ming-Jong Bai\(^16\), Chun-Yen Lin\(^10\), Wei-Wen Su\(^17\), Cheng-Hsia Chu\(^18\), Chih-Jen Chen\(^18\), Shui-Yi Tung\(^7\), Chi-Ming Tai\(^12\), Chih-Wen Lin\(^12\), Ching-Chu Lo\(^19\), Pin-Nan Cheng\(^20\), Yen-Cheng Chiu\(^20\), Chia-Chi Wang\(^21\), Jin-Shuang Cheng\(^22\), Wei-Lun Tsai\(^22\), Han-Chieh Lin\(^23\), Yi-Hsiang Huang\(^23,24\), Ming-Lun Yeh\(^1\), Chung-Feng Huang\(^1\), Meng-Hsuan Hsieh\(^1,2\), Jee-Fu Huang\(^1\), Chia-Yen Dai\(^1\), Wan-Long Chung\(^1\), Chiao-Li Khale Ke\(^25,26\), Ming-Lung Yu\(^1,27\) (T-COACH Study Group)

1. Hepatobiliary Section, Department of Internal Medicine, and Hepatitis Center, Kaohsiung Medical University Hospital; Hepatitis Research Center, School of Medicine and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
2. Health Management Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
3. Department of Internal Medicine, Chiayi Christian Hospital, Chiayi, Taiwan
4. Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan
5. Division of Hepatogastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
6. Department of Gastroenterology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
7. Division of Hepatogastroenterology, Department of Internal Medicine, China Medical
University Hospital, Taichung, Taiwan
8. Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
9. Division of Gastroenterology and Hepatology, Chi-Mei Medical Center, Liouying, Tainan
10. Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial Hospital, Keelung, Taiwan
11. Division of Gastroenterology, Department of Internal Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan
12. Division of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan,
13. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
14. Division of Gastroenterology and Hepatology, National Taiwan University Hospital, Taipei, Taiwan
15. Division of Gastroenterology, Department of Internal Medicine, Chang Bing Show-Chwan Memorial Hospital, Changhua, Taiwan
16. Division of Gastroenterology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan
17. Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
18. Division of Gastroenterology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan
19. Department of Internal Medicine, St. Martin De Porres Hospital - Daya, Chiayi, Taiwan
20. Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
21. Division of Gastroenterology, Department of Internal Medicine, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, New Taipei, Taiwan
22. Division of Gastroenterology and Hepatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
23. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
24. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
25. Department of Psychiatry, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

*Equal contribution

**Equal contribution

**Corresponding author: Ming-Lung Yu. Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung City 807, Taiwan. E-mail address: fish6069@gmail.com
Abstract

Background: Chronic hepatitis C (CHC) has been associated with major psychoses and interferon-based (IFN-based) therapy may cause psychiatric sequelae. We aimed to evaluate the effects of sustained virological response (SVR) on the incidence of major psychoses in a nation-wide Taiwanese CHC cohort.

Methods: 15,836 CHC Taiwanese who received IFN-based therapy were enrolled between 2003 and 2015. Of those, 12,723 patients were linked to the National Health Insurance Research Databases for the incidence of major psychoses. Death before major psychoses was considered a competing risk.

Results: Twenty-four patients developed new-onset major psychoses during 67,554 person-years (3.6 per 10,000 person-years), including 16 affective psychoses, seven schizophrenia, and one organic psychotic condition. The incidence of major psychoses and affective psychoses did not differ between the SVR and non-SVR groups. The 10-year cumulative incidence of schizophrenia were significantly higher in the non-SVR than in SVR patients (0.14% versus 0.04%, p=0.036). Cox subdistribution hazards showed that SVR and older age were associated with a significantly lower risk of schizophrenia (HR=0.18 and 0.17). SVR
was associated with decreased incidence of schizophrenia and majorly observed among patients with age<45 \( (p=0.02) \)

**Conclusions:** Successful IFN-based therapy might reduce the incidence of schizophrenia among CHC patients, especially among the younger.

**Keywords:** HCV; sustained virological response; competing risk; schizophrenia; psychiatric disorders
Introduction

Chronic hepatitis C virus (HCV) infections can lead to end-stage liver diseases and several extrahepatic manifestations(1), such as glucose dysregulation(2), renal function impairment(3), and central nervous system dysfunction(4). HCV has been associated with neuropsychiatric symptoms for years. Emerging evidence from active HCV replication in cerebrospinal fluid suggested that HCV may cross the blood-brain barrier, leading to neuroinvasion and neuroinflammation(5-7). Patients with chronic hepatitis C (CHC) had higher risks of fatigue and cognitive impairment, primarily in attention, concentration, psychomotor speed, and higher executive function(8, 9), which might be related to the alternation of serotonergic and dopaminergic neurotransmission(10). Patients with chronic HCV infections were also at higher risk of psychiatric disorders(11). Tension, depression, and confusion were significantly more severe in patients with end-stage liver disease due to HCV infection than in other liver transplant candidates\(^\text{14}\). One Swedish study found that patients with severe mental illness were associated with a six fold increase in risk for HCV infection(12).

Successful antiviral therapy with pegylated-interferon plus ribavirin has been associated with long-term benefits for patients with HCV, in terms of risk reduction in liver-related as well as extrahepatic complications, including hepatocellular carcinoma, liver
failure, cardiovascular events, diabetes and end-stage renal diseases (13-17). This therapy, through the achievement of sustained virological response (SVR), could improve attentional and neurocognitive functions (18, 19). However, the therapy did not affect the short-term frequency of depressive disorders (19). Another recent study demonstrated that achieving SVR did not matter for the frequency of psychiatric disorders among patients coinfected with human immunodeficiency virus (HIV)/HCV (20). Whether HCV eradication may reduce the risk of major psychiatric disorders remains unclear. In addition, interferon-based therapy itself may result in psychiatric sequelae, including depression, anxiety, irritability, and mood swings (21). Therefore, the long-term risk for major psychiatric disorders after anti-HCV treatment for patients with CHC patients on the needs to be clarified.

In the current study, we aimed to evaluate the long-term outcome of successful antiviral therapy on the new-onset of major psychiatric disorders, including ICD-9-CM codes 290-297, among patients with CHC by recruiting a large, real-world cohort. The study had well-defined baseline demographics, laboratory and virological data, and treatment responses to interferon-based therapy. Additionally, the study was linked to the National Health Insurance Research Databases (NHIRD) of Taiwan for data collection of consequent development of major psychiatric disorders during antiviral treatment and the post-treatment follow-up period.
Materials and Methods

Study Cohort

Taiwanese Chronic Hepatitis C Cohort (T-COACH) is a nationwide HCV registry cohort in Taiwan, which consists of 15,836 patients with CHC from 23 regional hospitals and medical centers enrolled between 1993 and 2015. The majority of patients enrolled between 2003 and 2015. The key eligible criteria for patients included in this study are that they are over 20 years old, CHC was diagnosed using liver histology or patients were seropositive for anti-HCV for > 6 months; patients were seropositive for HCV RNA; and patients had received interferon-based therapy for at least four weeks. Patients coinfected with HIV were excluded. The Taiwan Health Insurance administration began to reimburse anti-HCV agents for patients with CHC in 2003. A total of 75,431 patients with CHC were reimbursed with IFN-based therapy since 2003 (https://data.nhi.gov.tw/). The T-COACH cohort included approximately 21% of the CHC-treated population in Taiwan during this 13 year period.

Patient demographic characteristics, medical history, clinical features, and laboratory data were collected from participating sites, including host profiles (age, sex, biochemistry,
complete blood count, renal function, liver fibrosis) and virological characteristics (HCV genotype, HCV RNA level, and the virological responses after anti-HCV treatment). SVR was defined as HCV RNA seronegativity at 24 weeks after the end of antiviral therapy.

Advanced fibrosis was defined as a noninvasive, fibrosis-4 index (FIB-4) > 3.25. Liver cirrhosis was defined as any of the following: liver histology, transient elastography (FibroScan®; Echosens, Paris, France) > 12 kPa, acoustic radiation force impulse > 1.98 m/s, FIB-4 > 6.5, or the presence of clinical, radiological, endoscopic, or laboratory evidence of cirrhosis and/or portal hypertension.

Patient Consent Statement

This study was approved by the Institutional Review Boards at each participating hospital (IRB number: KMUHIRB-EXEMPT(I)-20170040). All patients provided written informed consents. All patient identifiers were removed or transcoding from these databases before analysis to protect personal privacy.
Study endpoints and linked databases

The primary endpoint of the current study was the development of newly diagnosed major psychiatric disorders reportable to NHIRD. The secondary endpoints were the development of sequela such as dementias, subacute delirium, schizophrenia, affective psychoses, paranoia and other organic psychotic disorders.

Approximately 23 million (99.7%) of the Taiwanese have been covered under the Taiwan National Health Insurance (NHI) since 1995 which has provided many comprehensive research databases. The registry of patients with catastrophic illness patients and the death registry were two widely used databases. The disease diagnoses were coded to identify diseases according to the International Classification of Diseases, 9th version, clinical modification (ICD-9-CM). A Taiwanese registry of the catastrophic illness included major illnesses such as carcinoma, renal failure, chronic mental disorders, congenital diseases, and rare diseases. The chronic psychiatric disorders in the catastrophic registration include ICD-9-CM codes 290 to 299. The codes for major psychoses assessed in this study were coded 290-dementias, 293.1-subacute delirium, 294-other organic psychotic conditions, 295-schizophrenia, 296-affective psychoses, and 297-paranoid. Code 299-psychiatric disorders with origin specific from childhood were excluded,
After excluding 934 patients seropositive for hepatitis B surface antigen and 2,042 without posttreatment virological data available, a total of 12,862 patients with CHC were linked to NHI catastrophic illness and death databases. After receiving data from the catastrophic illness registry, 110 patients were excluded for having a previous diagnosis of major psychiatric disorders and, according to the death registry, 29 died during or within six months of antiviral therapy and were excluded from the results. Data from the last course of antiviral therapy was retrieved if patients experienced more than one course of IFN-based therapy. New onset of major psychiatric disorders was calculated after the beginning of antiviral therapy. The final analysis consisted of 12,723 patients (Figure 1).

Statistical analysis

Continuous variables were expressed as the mean ± standard deviation (SD) or median/range. Category variables were expressed as number (percentage). Differences between groups were evaluated using a $X^2$ test (or Fisher’s exact test when $n$<5) for categorical data and Student’s t test (or ANOVA) for continuous data. The FIB-4 score for liver fibrosis was calculated as follows: $\text{FIB-4} = \frac{\text{AST}}{\text{upper limit of normal}} \times \frac{\text{Platelet}}{100}$. The estimated glomerular filtration rate (eGFR) for renal function was calculated as follows (27):

$$\text{eGFR} = 186 \times \text{Cr}^{1.154} \times \text{age}^{0.203} \times 0.742 \text{ (if female)}.$$ Person-years were calculated from the date
of the start of therapy to the date of the first diagnosis of any major psychoses, death or December 31, 2015, whichever occurred first. Annual incidences of any major psychoses were calculated as new-onset events divided by the person-years. The missing value was interpolated using the mean of the continuous variables.

Death before any major psychiatric disorders was considered a competing risk event. Therefore, we modified the Kaplan-Meier method according to Gray’s cumulative incidence method(28) and compared the incidence of newly diagnosed major psychiatric disorders between patients who achieved an SVR and those who did not achieve an SVR. Cox subdistribution hazards (CSH) models with univariate and age-, sex- adjusted multivariate were performed accordingly(29). Subgroups analysis were focused on special patients to understand the effects of successful antiviral therapy on new-onset major psychiatric disorders. Statistical analyses were performed using the SAS Enterprise Guide (SAS Institute Inc., Cary, NC, U.S.A.) and a p value<0.05 with a two-tailed test was considered to be statistically significant.
Results

Patients characteristics

A total of 12,723 patients with CHC, including 9,690 SVR and 3,033 non-SVR patients, were enrolled in the final analysis with a mean follow-up period of 5.3±2.9 years (range, 0.2-19.5). The baseline demographic profile of these patients is shown in Table 1. The mean age was 54.7 years and women accounted for 53.2% of the participants. The mean baseline HCV viral loads were 5.68 log IU/mL, 51.0% were infected with HCV genotype 1, 29.0% had advanced fibrosis, and 15.4% had liver cirrhosis. Factors associated with non-SVR were older age, men, higher BMI, diabetes, HCV genotype 1, higher viral load, and advance fibrosis or cirrhosis (see Table S1).

Events and incidence of major psychiatric disorders

During the follow-up period, 662 patients died without newly diagnosed major psychiatric disorders. Twenty-four patients developed new-onset major psychiatric disorders in 67,554 person-years of follow-up with an annual incidence of 3.6 per 10,000 person-years. Among 24 patients with new-onset major psychoses, 16 were affective psychoses, seven cases were schizophrenia, and one was an organic psychotic condition. No patients developed
dementias, paranoid, or subacute delirium. The annual incidence per 10,000 person-years was 2.4 for affective psychoses, 1.0 for schizophrenia, and 0.2 for the organic psychotic condition, respectively (Table 2).

**Impact of successful anti-HCV therapy on risk for major psychiatric disorders**

The annual incidence of major psychiatric disorders did not differ between the SVR and non-SVR groups (3.2 versus 4.6 per 10,000 person-years, respectively). The 1-, 3-, 5-, 8-, and 10-year cumulative incidence rates of major psychiatric disorders were 0.03%, 0.11%, 0.21%, 0.28%, and 0.28% for non-SVR patients compared to 0.03%, 0.10%, 0.19%, 0.25%, and 0.25% for SVR patients, respectively (crude HR/CI, 1.34/0.56-3.25, \(p=0.503\); adjusted HR/CI, 1.60/0.64-4.01, \(p=0.312\) for the CHS method and \(p=0.504\) for Gray’s method, respectively, Figure 2A). The annual incidence of affective psychoses was not statistically different between the SVR and non-SVR groups (2.5 versus 2.0 per 10,000 person-years, respectively). The 1-, 3-, 5-, 8-, and 10-year cumulative incidence rates of major psychiatric disorders were 0%, 0.07%, 0.07%, 0.14%, and 0.14% for non-SVR patients compared to 0.02%, 0.07%, 0.16%, 0.19%, and 0.19% for SVR patients, respectively (crude HR/CI, 0.76/0.22-2.66, \(p=0.667\), adjusted HR/CI, 0.87/0.24-3.18, \(p=0.829\) for the CHS method and \(p=0.667\) for Gray’s method, respectively, Figure 2B).
By contrast, the annual incidence of schizophrenia was substantially lower in the SVR compared to the non-SVR groups with a borderline significant (0.6 vs 2.6 per 10,000 person-years, $p=0.060$). The 1-, 3-, 5-, 8-, and 10-year cumulative incidence rates of schizophrenia were 0.03%, 0.03%, 0.14%, 0.14%, and 0.14% for non-SVR patients, which were significantly higher than those of SVR patients (0.01%, 0.02%, 0.02%, 0.04% and 0.04%, respectively, crude HR/CI, 4.36/0.98-19.28, $p$ value=0.053 for the CHS method and 0.036 for Gray’s method, respectively). After adjustment for age and sex, non-SVR patients had a significant 5.9-fold increased risk of schizophrenia compared to SVR patients (adjusted HR/CI: 5.89/1.32-26.19, $p=0.020$, Figure 2C).

Factors associated with new onset of major psychiatric disorders, affective psychoses, and schizophrenia among patients with CHC who received antiviral therapy

In univariate analysis, older age (> 45 years) and advanced hepatic fibrosis (FIB-4 $\geq 3.25$) were significantly associated with a lower risk of new-onset major psychiatric disorders (Table 3). After adjustment for age and sex, older age (> 45 years) and advanced hepatic fibrosis (FIB-4 $\geq 3.25$) remained associated with lower risk of new-onset major psychiatric disorders (adjusted HR/CI, 0.42/0.18-1.00 and 0.23/0.05-1.01, respectively, both $p=0.051$, borderline significance). Female patients with CHC patients had a significantly higher risk of
new-onset major psychiatric disorders after anti-HCV therapy when compared to male patients did (adjusted HR/CI, 2.42/1.07-5.48, \( p=0.034 \)). Similar results also were observed on affective psychoses. Being a woman was the only factor predictive of affective psychoses after adjustment for age (HR/CI, 4.27/1.31-13.89, \( p=0.016 \)) (Data not shown).

Table 4 shows the factors associated with the risk of schizophrenia among patients with CHC after anti-HCV therapy. After adjustment for age and sex, SVR and older age (> 45 years) were significantly associated with a lower risk of developing schizophrenia (HR/CI, 0.18/0.04-0.90, \( p=0.037 \); 0.17/0.04-0.71, \( p=0.015 \)).

We further analyzed the impact of successful anti-HCV therapy on the risk of major psychiatric disorders, stratified by age and sex. Among patients with age < 45, non-SVR patients had a 3.95-fold and 14.78-fold increased risk of major psychiatric disorders \( (p=0.04) \) and schizophrenia \( (p=0.02) \), respectively, when compared to patients with SVR (Figure 3A).

The risk of affective psychoses was similar between SVR and non-SVR patients among the younger patient population. There was no difference between SVR and non-SVR groups in terms of major psychiatric disorders, schizophrenia, and affective psychoses among the older patient population (>45 years, Figure 3A). The risks of major psychiatric disorders,
schizophrenia and affective psychoses were also similar between SVR and non-SVR patients in both male and female subpopulations (Figure 3B).

Discussion

In the current nation-wide, cohort study with a total of 67,554 person-years follow-up, the annual incidence of major psychiatric disorders, affective psychoses, schizophrenia, and organic psychotic condition per 10,000 person-years was 3.6, 2.4, 1.0, and 0.2, respectively, among patients with CHC after interferon-based therapy. The risk of major psychiatric disorders and affective psychoses did not differ between patients who did and did not achieve an SVR. However, there was an 83% risk reduction of schizophrenia for patients with CHC who achieved an SVR compared to those who did not. The benefits of successful antiviral therapy in reducing the risk of schizophrenia among patients with CHC were majorly observed among the population younger than 45 years.

Little published data on the incidence of major psychiatric disorders, affective psychoses, and schizophrenia comparison the general population and patients with viral hepatitis in Taiwan was available. One population-based cohort from Taiwan NHIRD reported that the incidence rate of bipolar disorders was significantly higher among HBV/HCV co-infected patients, but not in HBV mono-infected or HCV-mono-infected patients, when compared to
general controls (3.62, 1.79, 2.23, and 1.14 per 10,000 person-years, respectively)(30).

Similarly, they observed that antiviral therapy for HBV or HCV had no impact on the incidence rate of bipolar disorders(30). In the present study, we reported that treatment responses to anti-HCV therapy did not influence on the incidence of major psychiatric disorders and affective disorders.

In a large-scale, Dutch, cohort study of over 350,000 subjects, the annual incidence rate of schizophrenia was 1.2 per 10,000 person-years in the general population during a 10-year follow up(31). A systematic review reported the incidence rate of schizophrenia was about 1.2 to 1.5 per 10,000 person-years and much variance around the world(32, 33). The peak incidence for males and females is in the decade 15–24(34). In the present study, we found that the incidence rate of schizophrenia was 2.6 per 10,000 person-years in HCV non-SVR patients and only 0.6 per 10,000 person-years in HCV SVR patients. A gender-specific difference in the incidence of schizophrenia was observed in the younger population of this cohort. Men had a significantly higher incidence rate of schizophrenia spectrum disorders and schizophrenia with a 1.6- and 2.0-fold risk, respectively, when compared with women for subjects <35 years old, but not in those with age ≥ 35 years old(31). However, we did not observe a gender effect on the risk of schizophrenia in this HCV cohort due to few patients
with age <35 years old. By contrast, compared with SVR patients, non-SVR patients had a 5.9-fold risk of developing schizophrenia in the general CHC population. This increased to 14.8-fold risk among the CHC population younger than 45 years. Our results suggested that continuous CHC infections might be associated with a higher risk of schizophrenia, especially among younger patients. Remarkably, we observed that the mean age of the seven patients with CHC who presented with newly diagnosed schizophrenia was 42.7 years, which was older than the usual onset age of schizophrenia in the early 30s (34). Whether the late-onset of schizophrenia is related to HCV exposure needs further study.

HCV infection as a brain fog affects attention, concentration, memory, and mood, which further impairs health-related quality of life (HRQOL) and work productivity (35, 36). These disturbances might be reduced after HCV is eradicated. Several proteins might play essential roles in the association between HCV and psychiatric disorders. Another review has shown that four proteins (DISC1, neuregulin, the D2 dopamine receptor and transcription factor 4), that cause schizophrenia susceptibility were homologous with that of hepatitis C virus (37). HCV infection as a risk-promoting factor may promote schizophrenia if the human genes encode for the homologous product. Therefore, schizophrenia is perhaps preventable by the homologous pathogen elimination. By contrast, interferon-based treatment may also often
lead to psychiatric adverse effects or mental disorders in a subset of patients with CHC(38).

Microarray analysis showed the link between interferon-stimulated-exonuclease-gene 20kDa (ISG20), interferon-related neuropsychiatric toxicity, and the response to interferon-based treatment for patients co-infected with HIV/HCV(39).

Recent advances in the development of new anti-HCV regimens with interferon-free directly-acting antivirals (DAA) has not only greatly improved the treatment efficacy but also largely decreased the frequency and magnitude of adverse events(40, 41). Over 98% of patients with CHC achieved an SVR and HRQOL has been shown to improve as early as 4 weeks into the treatment, through the end of treatment, and 4 weeks post-treatment in an Asian study(42). The change in cytokines (interleukin-8 and interleukin-10), and neurotransmitters (dopamine and tryptophan) among patients with CHC who receive interferon-free DAA therapy might influence patients mental and emotional health before, during, and post-antiviral therapy(43). The long-term impact of SVR by using interferon-free DAA regimens on the incidence of major psychiatric disorders remains to be studied.

The limitation of the current study is that only major and defined diagnosis mental illness were enrolled at the registry database for patients with catastrophic illnesses. The limited index cases would also restrict the interpretation of the study outcome. Additionally,
the rare incidence of major psychiatric disorders in the study, as well as in the general population, makes it challenging to obtain a substantial number of patients with significant events for such studies. Finally, the database lacks detailed classification information (e.g. ICD-9-CM: 291 alcohol-induced psychosis disorders) and etiology codes (the 4th code of ICD-9-CM). A longer follow-up period and more patients with CHC who receive DAA are needed for further verification.

In conclusion, successful interferon-based anti-HCV therapy might reduce the incidence rate of schizophrenia, especially among the younger subpopulation, indicating the urgency in treating patients with CHC as young as possible. Further study with a large cohort of interferon-free DAA-treated patients and a longer follow-up period is warranted.
Acknowledgements

The study was supported by grants from Kaohsiung Medical University (KMU-DK107004 and MOST 108-2314-B-037-066-MY3), Kaohsiung Medical University Research Center Grant (KMU-TC108A04, KMU-TC108B07) and Kaohsiung Medical University Hospital (KMUH 106-6R05 and MOHW 108-TDU-B-212-133006). The authors would like to thank the T-COACH investigators who provided the patients for analysis. All linkage databases were supported from Health and Welfare Data Science Center, Taiwan. We are grateful to Kaohsiung Medical University for providing administrative and funding support.

Conflict of interest

In the present study, all authors have no conflict of interest.
**Figure legends**

**Figure 1.** Patient flow chart from T-COACH and linkage to Taiwan NHIRD

**Figure 2.** Incidence of major psychiatric disorders, affective psychoses and schizophrenia between SVR and non-SVR patients after anti-HCV therapy with death as competing risk

**Figure 3.** Ten-year cumulative incidence and cox subdistribution hazards model of major psychoses, schizophrenia, and affective psychoses between SVR and non-SVR HCV patients among subgroups of age (A) and gender (B) with death as competing risk
References

1. Younossi ZM, Henry L, J PO, et al. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644-653.

2. Huang JF, Yu ML, Dai CY, et al. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol 2008;103:1933-1940.

3. Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790.

4. Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders - A review. J Adv Res 2017;8:139-148.

5. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-39.

6. Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 2002;76:10064-10068.

7. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004;78:5170-5183.

8. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003;10:81-86.
9. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-439.

10. Weissenborn K, Ennen JC, Bokemeyer M, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624-1630.

11. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001;42:411-415.

12. Bauer-Staeb C, Jorgensen L, Lewis G, et al. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry 2017;4:685-693.

13. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-744.

14. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:495-503.

15. Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 2014;61:67-74.

16. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon
reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.

Aliment Pharmacol Ther 2007;25:1029-1037.

17. Yu ML, Huang CF, Yeh ML, et al. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. Clin Cancer Res 2017;23:1690-1697.

18. Kraus MR, Schafer A, Teuber G, et al. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology 2013;58:497-504.

19. Barbosa MED, Zaninotto AL, de Campos Mazo DF, et al. Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin. BMC Gastroenterol 2017;17:122.

20. Michel L, Lions C, Winnock M, et al. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS) HEPAVIH CO13 cohort]. HIV Med 2016;17:758-765.

21. Al-Omari A, Cowan J, Turner L, Cooper C. Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis. Can J Gastroenterol 2013;27:575-581.

26
22. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.

23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.

24. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.

25. Lin YH, Yeh ML, Huang CI, et al. The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. Kaohsiung J Med Sci 2016;32:362-366.

26. Wang CC, Liu CH, Lin CL, et al. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. J Formos Med Assoc 2015;114:923-928.

27. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.

28. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a
competing risk. Ann Stat 1988;16:1141-1154.

29. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.

30. Chong LW, Hsu CC, Lee CY, et al. Association of viral hepatitis and bipolar disorder: a nationwide population-based study. J Transl Med 2018;16:173.

31. Sutterland AL, Dieleman J, Storosum JG, et al. Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. Soc Psychiatry Psychiatr Epidemiol 2013;48:1357-1365.

32. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76.

33. Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am 2007;30:323-338.

34. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993;162:80-86.

35. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015;63:337-345.

36. Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol 2015;21:11974-11983.
37. Carter CJ. Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes. J Pathog 2011;2011:128318.

38. Adinolfi LE, Nevola R, Lus G, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 2015;21:2269-2280.

39. Katsounas A, Rasimas JJ, Schlaak JF, et al. Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients. J Med Virol 2014;86:1323-1331.

40. Huang CF, Yeh ML, Huang CI, et al. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. BMJ Open 2019;9:e026703.

41. Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided". therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-1442.

42. Younossi ZM, Stepanova M, Chan HL, et al. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. Medicine (Baltimore) 2016;95:e2702.

43. Golabi P, Elsheikh E, Karrar A, et al. The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). Medicine (Baltimore) 2016;95:e5066.
Table 1. Baseline patients demographic characteristics and virological features

| Variables                        | N     | Mean ± SD or n (%) |
|----------------------------------|-------|--------------------|
| Age                              | 12,723| 54.65±11.35        |
| >45 years                        |       | 10,391 (81.7)      |
| Female                           | 12,723| 6,766 (53.2)       |
| BMI (kg/m²)                      | 12,723| 25.01±3.50         |
| Diabetes history                 | 6,950 | 1,261 (18.1)       |
| Hypertension history             | 6,950 | 1,411 (20.3)       |
| Dyslipidemia history             | 6,950 | 628 (9.0)          |
| HCV genotype 1                   | 11,815| 6,028 (51.0)       |
| HCV RNA (log IU/mL)              | 11,167| 5.68±0.99          |
| >400,000 IU/mL                   |       | 6,799 (60.9)       |
| AST (IU/L)                       | 12,723| 91.10±64.48        |
| ALT (IU/L)                       | 12,723| 137.49±110.27      |
| FIB-4                            | 12,723| 2.94±2.52          |
| ≥3.25 (advance fibrosis)         |       | 3,694 (29.0)       |
| Liver cirrhosis                  | 12,723| 1,960 (15.4)       |
| eGFR (ml/min/1.73m²)             | 12,723| 99.55±34.96        |
| Follow-up duration (years)       | 12,723| 5.31±2.94          |
| Follow-up person-years           | 67,554|                   |

Note: N, case number; SD, standard deviation; HCV, hepatitis C virus; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis-4 score; eGFR, estimated glomerular filtration rate
Table 2. Relationship between anti-HCV responses and incidence of major psychiatric disorders, affective psychoses and schizophrenia

|                          | Total (n=12,723) | SVR (n=9,690) | non-SVR (n=3,033) | P value |
|--------------------------|------------------|---------------|-------------------|---------|
| Follow-up duration (years) | 5.31±2.94        | 5.42±2.97     | 4.97±2.78         | <0.0001 |
| Median (Range)           | 5.16 (0.22-19.49)| 5.27 (0.23-19.49)| 4.76 (0.82-15.04)|         |
| Follow-up person-years   | 67,554           | 52,493        | 15,061            |         |
| Events, n (annual incidence per 10,000 person-year) |       |               |                   |         |
| Major psychoses          | 24 (3.6)         | 17 (3.2)      | 7 (4.6)           | 0.540   |
| -Affective psychoses     | 16 (2.4)         | 13 (2.5)      | 3 (2.0)           | 0.776   |
| -Schizophrenia           | 7 (1.0)          | 3 (0.6)       | 4 (2.6)           | 0.060   |
| -Others                  | 1 (0.2)          | 1 (0.2)       | 0 (0.0)           | NA      |

†294- organic psychotic conditions

Note: HCV, hepatitis C virus; SVR, sustained virological response
Table 3. Cox subdistribution hazards model for risk factors of major psychiatric disorders among patients with CHC who achieved antiviral therapy

Note: HR, hazard ratio; CI, confidence intervals; BMI, body mass index; FIB-4, Fibrosis-4 index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; SVR, sustained virological response

|_variables | cumulative incidence (%) | crude HR (95% CI) | p value | adjusted HR (95% CI) | p value |
|-----------|--------------------------|--------------------|---------|----------------------|---------|
| Age (years) | | | | | |
| <45 | 0.39 | 1 | | | |
| ≥45 | 0.14 | 0.39 (0.17-0.88) | 0.024 | 1 | 0.42 (0.18-1.00) | 0.051 |
| Sex | | | | | |
| Male | 0.13 | 1 | | | |
| Female | 0.25 | 1.89 (0.83-4.29) | 0.127 | 1 | 2.42 (1.07-5.48) | 0.034 |
| BMI (kg/m²) | | | | | |
| <24 | 0.25 | 1 | | | |
| ≥24 | 0.16 | 0.63 (0.28-1.40) | 0.256 | | | |
| Diabetes | | | | | |
| No | 0.19 | 1 | | | |
| Yes | 0.4 | 2.09 (0.72-6.08) | 0.177 | | | |
| Hypertension | | | | | |
| No | 0.25 | 1 | | | |
| Yes | 0.14 | 0.55 (0.13-2.40) | 0.426 | | | |
| Dyslipidemia | | | | | |
| No | 0.24 | 1 | | | |
| Yes | 0.16 | 0.73 (0.10-5.54) | 0.764 | | | |
| HCV genotype | | | | | |
| G1 | 0.18 | 1 | | | |
| G2 | 0.19 | 0.63 (0.22-1.80) | 0.39 | | | |
| HCV RNA (IU/mL) | | | | | |
| ≤400,000 | 0.14 | 1 | | | |
| >400,000 | 0.16 | 1.28 (0.47-3.50) | 0.634 | | | |
| AST (IU/L) | | | | | |
| <80 | 0.21 | 1 | | | |
| ≥80 | 0.16 | 0.67 (0.29-1.56) | 0.358 | | | |
| ALT (IU/L) | | | | | |
| <80 | 0.21 | 1 | | | |
| ≥80 | 0.18 | 0.70 (0.30-1.61) | 0.397 | | | |
| FIB-4 | | | | | |
| <3.25 | 0.24 | 1 | | | |
| ≥3.25 | 0.05 | 0.21 (0.05-0.91) | 0.037 | 1 | 0.23 (0.05-1.01) | 0.051 |
| Liver Cirrhosis | No | 0.23 | 1 | | | |
|                        | Yes | 0.05 | 0.22 (0.03-1.67) | 0.145 |
|------------------------|-----|------|------------------|-------|
| eGFR (ml/min/1.73m$^2$)| ≥60 | 0.17 | 1                | 0.064 |
|                        | <60 | 0.53 | 3.13 (0.94-10.50)|       |
| Viral Response         | SVR | 0.18 | 1                | 1     |
|                        | Non-| 0.23 | 1.34 (0.56-3.25) | 0.503 |
|                        | SVR |     | 1.56 (0.62-3.95) | 0.349 |
Table 4. Cox subdistribution hazards model of the risk factors of schizophrenia among patients with CHC who achieved antiviral therapy

| Variables          | Cumulative Incidence (%) | Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value |
|--------------------|--------------------------|-------------------|---------|----------------------|---------|
| Age (years)        |                          |                   |         |                      |         |
| <45                | 0.17                     | 1                 | 1       | 0.17 (0.04-0.81)     | 0.015   |
| ≥45                | 0.03                     | 0.19 (0.04-0.81)  | 0.025   | 0.17 (0.04-0.71)     | 0.015   |
| Sex                |                          |                   |         |                      |         |
| Male               | 0.07                     | 0.46 (0.09-2.36)  | 0.355   | 0.60 (0.14-2.59)     | 0.492   |
| Female             | 0.03                     |                   |         |                      |         |
| BMI (kg/m²)        |                          |                   |         |                      |         |
| <24                | 0.07                     | 1                 | 1       | 0.72 (0.16-3.28)     | 0.673   |
| ≥24                | 0.05                     |                   |         |                      |         |
| Diabetes           |                          |                   |         |                      |         |
| No                 | 0.05                     | 1                 | 1       | 3.19 (0.50-20.35)    | 0.219   |
| Yes                | 0.16                     |                   |         |                      |         |
| Hypertension       |                          |                   |         |                      |         |
| Yes                | 0.07                     | 0.96 (0.11-8.46)  | 0.972   |                      |         |
| No                 | 0.07                     | 1                 | 1       |                      |         |
| Dyslipidemia       |                          |                   |         |                      |         |
| No                 | 0.08                     | 1                 | 1       |                      |         |
| Yes                | 0                       | NA                | NA      | 0.54 (0.12-2.34)     | 0.407   |
| HCV genotype       |                          |                   |         |                      |         |
| G1                 | 0.07                     | 1                 | 1       |                      |         |
| G2                 | 0                       | NA                | NA      |                      |         |
| HCV RNA (IU/mL)    |                          |                   |         |                      |         |
| ≤400,000           | 0.05                     | 1                 | 1       | 1.01 (0.17-5.98)     | 0.99    |
| >400,000           | 0.04                     |                   |         |                      |         |
| AST (IU/L)         |                          |                   |         |                      |         |
| <80                | 0.08                     | 1                 | 1       |                      |         |
| ≥80                | 0.02                     | 0.18 (0.02-1.58)  | 0.122   |                      |         |
| ALT (IU/L)         |                          |                   |         |                      |         |
| <80                | 0.07                     | 1                 | 1       |                      |         |
| ≥80                | 0.05                     | 0.54 (0.12-2.34)  | 0.407   |                      |         |
| FIB-4              | <3.25                    | 0.08              | 1       |                      |         |
|                                   | 0  | NA  | NA  |
|-----------------------------------|----|-----|-----|
| Liver Cirrhosis                   |    |     |     |
| No                                | 0.07 | 1   |     |
| Yes                               | 0  | NA  | NA  |
| eGFR (ml/min/1.73m²)              |    |     |     |
| ≥60                               | 0.05 | 1   |     |
| <60                               | 0.18 | 3.61 (0.43-30.15) | 0.236  |
| Viral Response                    |    |     |     |
| SVR                               | 0.03 | 1   | 1   |
| Non-SVR                           | 0.13 | 4.36 (0.98-19.28) | 0.053  | 5.41 (1.11-26.44) | 0.037  |

Note: HR, hazard ratio; CI, confidence intervals; BMI, body mass index; FIB-4, Fibrosis-4 index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; SVR, sustained virological response
Figure 1. Patient flow chart from T-COACH and linkage to Taiwan NHIRD

15,836 Hospital-based chronic HCV patients with IFN-based

Exclusion
1. HBV seropositive (n=934)
2. SVR unavailability (n=2,042)

12,862 Hospital-based chronic HCV patients with IFN-based

Exclusion
1. Mortality during therapy (n=29)
2. Previous diagnosis of major psychoses before therapy (n=110)

52,493 person-year follow up
3,033 Non-SVR
Median 4.8 years
(0.8-15.0 years)

9,690 SVR
Follow up
Median: 5.3 years
(0.2-19.5 years)

26 million Taiwan population of the NHI research database

- 272,946 patients diagnosed major psychoses from NHI catastrophic illness database
- 3,378,581 patients died from NHI death database until December 31, 2015

New onset
- 7 major psychoses
  (annual incidence: 0.046%)

New onset
- 17 major psychoses
  (annual incidence: 0.032%)
Figure 2. Incidence of major psychiatric disorders, affective psychoses and schizophrenia between SVR and non-SVR patients after anti-HCV therapy with death as competing risk

(A) Major psychiatric disorders

| Years | 1   | 3   | 5   | 8   | 10  |
|-------|-----|-----|-----|-----|-----|
| SVR   |     |     |     |     |     |
| No. at risk | 9,172 | 7,548 | 5,219 | 1,876 | 922 |
| Cumulative Incidence (%) | 0.03 | 0.10 | 0.19 | 0.25 | 0.25 |
| Non-SVR |     |     |     |     |     |
| No. at risk | 2,854 | 2,282 | 1,427 | 432  | 197 |
| Cumulative Incidence (%) | 0.03 | 0.11 | 0.21 | 0.28 | 0.28 |
(B) Affective psychoses

p value for Gray’s method = 0.667

Crude HR (95% CI) = 0.76 (0.22-2.66), p=0.667
Age-, sex-adjusted HR (95% CI) = 0.87 (0.24-3.18), p=0.829

|                  | Years | 1    | 3    | 5    | 8    | 10   |
|------------------|-------|------|------|------|------|------|
|                  | No. at risk | 9,173| 7,551| 5,222| 1,877| 922  |
| SVR              | Cumulative Incidence (%) | 0.02 | 0.07 | 0.16 | 0.19 | 0.19 |
|                  | No. at risk | 2,855| 2,283| 1,428| 432  | 306  |
| Non-SVR          | Cumulative Incidence (%) | 0    | 0.07 | 0.07 | 0.14 | 0.14 |
(C) Schizophrenia

- Crude HR (95% CI) = 4.36 (0.98-19.28), p = 0.053
- Age-, sex-adjusted HR (95% CI) = 5.89 (1.32-26.19), p = 0.020

Cumulative Incidence (%)

| Years | 1   | 3   | 5   | 8   | 10  |
|-------|-----|-----|-----|-----|-----|
| No. at risk |
| **SVR** |
| Cumulative Incidence (%) |
| 0.01  | 0.02 | 0.02 | 0.04 | 0.04 |
| No. at risk |
| **Non-SVR** |
| Cumulative Incidence (%) |
| 0.03  | 0.03 | 0.14 | 0.14 | 0.14 |
Figure 3. Ten-year cumulative incidence and cox subdistribution hazards model of major psychoses, schizophrenia, and affective psychoses between SVR and non-SVR HCV patients among subgroups of age (A) and gender (B) with death as competing risk.